Dec. 17, 2015
Description
Among cannabinoid receptors, CB1 is the most abundant G-protein coupled receptor present in the brain, and it plays an important role in rewards, learning, memory, motor control and addiction. Alcohol addiction has been observed to be linked with up/down regulation of CB1 receptor. Currently available CB1 antagonists, though useful in alcohol addiction treatment, are associated with adverse psychiatric effects. This invention discloses the development and use of novel class of allosteric compounds that negatively module the response of such endogenous cannabinoids without associated limitations as observed with prior art modulators.
oTreatment of metabolic disorders
oTreatment of cardiovascular diseases
oTreatment of substance abuse disorders
oTreatment of neurodegenerative disorders
The allosteric compounds:
•Are synthetic derivatives
•Effectively allow for an affinity modulation, altering association or dissociation rates
•Are associated with a higher subtype selectivity as compared to their orthosteric counterparts
•Are capable of fine tuning the downstream signaling, leading to a functional selectivity
•Provide effective therapeutic benefits with minimal or no side effects
•Are associated with a prolonged duration of action
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
adverse psychiatric effects
prior art modulators
alcohol addiction treatment
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium